Institutional investors purchased a net $5.6 million shares of MYGN during the quarter ended September 2016 and now own 129.06% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CAMBER CAPITAL MANAGEMENT LLC Bought 3.8 Million shares of Myriad Genetics Inc
DANSKE BANK A/S (INVT MGMT) Bought 65.5 Thousand shares of Myriad Genetics Inc
CANDRIAM BELGIUM SA Bought 59.0 Thousand shares of Myriad Genetics Inc